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Major advances have been achieved during the past 40 years in the epidemiology, etiology,
pathology, endocrinology, immunology, diagnosis, and treatment ofmolar pregnancy (MP) and
gestational trophoblastic neoplasia (GTN). MP is now recognized as composing two distinct
entities-complete and partial, with distinct histopathology, genetics, and clinical presenta-
tions. Proper management is dependent on a thorough understanding of each type. Early
diagnosis and effective treatment ofpatientswith GTN has resulted in 100 percent cure rates in
non-metastatic disease and in the majority of patients with metastases. In most instances,
resistant disease leading to death results from delayed diagnosis and overwhelming tumor
burden. Moreover, in most instances successful treatment can be accomplished with preserva-
tion offertility and normal pregnancy outcome anticipated. A rare variant ofchoriocarcinoma
called placental site trophoblastic tumor (PSTT) has been described, which, although curable
by surgery when localized, is usually fatal when disseminated. It is anticipated that during the
decade ofthe nineties the scientific work in progress will lead to earlier diagnosis and improved
survival in resistant cases.
Thirty-five years have elapsed since the first patient with metastatic choriocarci-
noma was successfully treated with chemotherapy at the National Cancer Institute.
Since that momentous occasion, which the late Arthur T. Hertig, Professor of
Pathology, Harvard Medical School, called "God's first cancer, man's first cure,"
much has been accomplished in our understanding ofthis fascinating and enigmatic
group ofdiseases.
The following is a summary of the current status of knowledge about this
condition, which is now referred to as gestational trophoblastic neoplasia (GTN),
emphasizing those aspects which are most important for the clinician to understand
when confronted with a patient who is afflicted bythis illness.
The topics to be discussed include evolving concepts ofmolar pregnancy, manage-
ment of gestational trophoblastic tumors, staging and prognostic factors, placental
site trophoblastic tumors, and the subsequent reproductive performance of women
following treatment for molar pregnancy and gestational trophoblastic disease.
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EVOLVING CONCEPTS OF MOLAR PREGNANCY
Pathology
Molarpregnancy (MP) is composed oftwo separate entities, partial and complete,
which are distinct in terms of histopathology, chromosome pattern, and clinical
presentation. Chorionic villi in complete moles are diffusely hydropic and are
enveloped by hyperplastic and atypical trophoblast [1]. Complete moles generally
have no identifiable embryonic or fetal tissue. In contrast, partial moles are com-
posed of two populations of chorionic villi. While some villi appear reasonably
normal, others have hydropic swelling and focal trophoblast hyperplasia [2]. Hy-
dropic villi may also have markedly irregular scalloping and stromal trophoblastic
inclusions. Fetal embryonic tissues are often identified with partial moles, but these
fetuses generally exhibit the malformations oftriploidy, including syndactyly, hydro-
cephalus, and growth retardation [3]. Infrequently, fetuses associated with partial
moles are live-born.
ChromosomalPattem
Approximately 90 percent of complete moles have a 46 XX karyotype, and the
molar chromosomes are of paternal origin [4-6]. Generally a haploid (23X) sperm
fertilizes an ovum and then duplicates its own chromosomes; the maternal chromo-
somes maybe either inactive or absent [7]. While most complete moles have a 46XX
karyotype, 6-10 percent have a 46XY chromosomal pattern; again, all the chromo-
somes are paternal in origin [8]. The 46 XY complete mole apparently results from
fertilization ofan empty ovumby two separate sperm [9].
About two-thirds of partial moles have a triploid karyotype, resulting from
fertilization of an apparently normal ovum by two sperm [10,11]. The remaining
one-third of partial moles have a diploid karyotype (46XX or 46XY). It may,
however, be difficult to differentiate partial mole from a twin gestation coexisting
with a complete mole.
Experiments involving nuclear transplantation in mice provide important insights
into thegenesisofmolarpregnancy [12]. Paternal ormaternal nucleifrom earlygerm
cells were transferred to an egg inwhich the female pronucleus was removed. When
"fertilized" eggs contained two maternal sets of chromosomes, the embryo devel-
oped to the 25-somite stage, with poor growth of extra-embryonic tissues. When
"fertilized" eggs contained two paternal sets ofchromosomes, like a complete mole,
the embryo developed only to the six-somite stage and degenerated, and the
trophoblastic growth was exuberant and hyperplastic. Therefore, the maternal
genome is particularly important for regulating the growth and development of the
embryo, while the paternal genome is crucial to controlling proliferation of extra-
embryonic tissues. The central theme ofmolar trophoblastic neoplasia appears to be
anexcessive amountofpaternalchromosomes,whichinducestrophoblastic hyperpla-
sia.
ClinicalPresentation
The most common presenting symptom in patients with complete mole is vaginal
bleeding (97 percent) [13]. Half the patients present with signs and symptoms of
marked trophoblasticgrowth, including excessive uterine size, high human chorionic
gonadotropin (hCG) levels, and prominent ovarian theca lutein cysts. These patients
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are also predisposed to develop such medical complications as toxemia (27 percent),
hyperthyroidism (7 percent), and acute respiratory insufficiency (2 percent), which
usually become clinically apparent following evacuation.
In contrast, a patient with partial mole usually does not exhibit the dramatic
clinical features demonstrated by complete mole. Only 4-11 percent have excessive
uterine enlargment. Theca lutein cysts, hyperthyroidism, respiratory insufficiency,
and toxemia are rare. Furthermore, pre-evacuation hCG levels are normal or low in
the majority of cases (94 percent). In fact, the pre-evacuation clinical diagnosis
usuallyis eithermissed orincomplete abortion in over 90percent and the diagnosis is
made only after histologic review ofcurettage specimens.
Ultrasonic Findings
Complete molar pregnancy produces a characteristic vesicular sonographic pat-
tern because of the marked generalized swelling of chorionic villi. Ultrasound may
not, however, be able to identify small molar villi in the early first trimester or
distinguish an early mole from degenerating chorionic villi. Correlation of the
ultrasonic features with the hCG level is essential in establishing the correct
diagnosis.
Ultrasonography has been less accurate in the diagnosis of partial molar preg-
nancy. Approximately 25 percent ofpatientswithpartial mole exhibit placental cystic
spaces, and a fetuswith multiple anomalies suggestive oftriploidywill be noted in 10
percent ofcases. Arecent review ofultrasounds at the Brigham &Women's Hospital
in 22 patients with partial moles and 33 first-trimester missed abortions reveal two
sonographicfindingswhich appear tocorrelate clinicallywith the histologicdiagnosis
of partial mole: cystic changes in the placenta, and > 1.5 ratio in the transverse to
anterior-posterior diameter of the gestational sac. The latter finding may be part of
the embryopathy oftriploidy [16].
PersistentDisease FollowingEvacuation
Complete moles give rise to persistent GTN in about 20 percent of patients
[17-19]. Patientswho have signs ofmarked trophoblastic growth, including excessive
uterine size, high hCG levels, and theca lutein cysts, have a 40-50 percent chance of
developingpersistent tumorswhich require intervention, and these are designated as
high-risk moles. In contrast, only 4-7 percent of moles without signs of exuberant
trophoblastic growth develop persistent disease and therefore are characterized as
low-risk moles.
The risk of developing persistent GTN in patients with partial moles is approxi-
mately 3-4 percent, which is similar to that seen in complete moles without evidence
of exuberant trophoblastic growth [20]. In a recent series from the New England
Trophoblastic Disease Center (NETDC), patients with partial mole who developed
persistent disease did not havepathologic orclinical features thatdistinguished them
from other patients with partial mole [21]. Thus partial molar patients are generally
considered to be low-risk. All ofthe patients with persistent tumor afterpartial mole
had non-metastatic disease and achieved complete remission after one or two
courses of single-agent chemotherapy. There are, however, reported cases of meta-
static disease following partial moles, so careful follow-up after evacuation is
essential, and a thorough examination for metastatic disease should be carried out
before treatment is undertaken.
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STAGING AND PROGNOSTIC FACTORS
The staging of GTN has been the subject of controversy among gynecologists for
years, and there are no signs on the horizon of resolving the conflict. The first
attempt at staging emerged from the clinical classification developed at the National
Cancer Institute (NCI). All patients were divided initially into two groups on the
basis ofthe extent ofdisease (i.e., non-metastatic versus metastatic) [22]. In 1965, an
analysis of the first ten years' experience at the NCI led to the conclusion that
patients with metastatic disease should be subdivided into good prognosis and poor
prognosis on the basis of certain prognostic factors which included the duration of
disease, the hCG level, the presence ofbrain or liver metastases, failed response to
initial chemotherapy, and the type ofantecedent pregnancy [23].
In 1985, the International Federation ofGynecologists and Obstetricians (FIGO)
began to report data on GTN using an anatomic staging system which was based on
postmortem studies inover450patients carried outbythe CapitalHospital in Beijing
by Sung and colleagues [24]. In this system, stage I includes all patients with tumor
confined to the uterus. Stage II comprises all patients with tumor outside the uterus
but localized to the vagina and/or pelvis. Stage III includes all patients with
pulmonary metastases with or without uterine, vaginal, or pelvic involvement. Stage
IV includes patients who have far-advanced disease with involvement of the brain,
liver, kidneys, or gastrointestinal tract. Patients with stage IV disease are in the
highest risk category because they are most likely to be resistant to chemotherapy.
Stage IV tumors generally have the histologic pattern of choriocarcinoma and most
commonly follow a non-molar pregnancy.
The main advantage of the FIGO staging system is the fact that it most closely
resembles that used in the staging of other gynecologic malignancies. Its main
drawback lies in the fact that it lacks a logical prognostic sequence on which to base
therapy, since there are patients in each category who are at greater risk of
developing drug resistance.
In order to resolve this problem, in 1983 the World Health Organization (WHO)
endorsed the use of a prognostic scoring system, based on one developed by
Bagshawe, which reliably predicts the potential for chemotherapy resistance [25]. In
that system, high scores indicate greater potential for drug resistance and the need
for intensive combination chemotherapy to attain remission.
A recent poll ofmembers ofthe Society for Gynecologic Oncologists revealed that
the NCI classification was the one mostwidely utilized by its members. Nonetheless,
we feel that anatomic staging plays an important role in collecting and comparing
data from different centers throughout theworld.
MANAGEMENT OF GESTATIONAL TROPHOBLASTIC NEOPLASMS
The optimal management of GTN requires a thorough evaluation ofthe extent of
disease, accurate pathologic interpretation of available material, availability of a
reliable hCG assay, an understanding ofthe natural history oftrophoblastic tumors,
and familiaritywith treatment protocols which have proven mosteffective inthe past.
Diagnostic Tests
All patients with persistent tumors, regardless of the antecedent pregnancy,
should undergo a thorough evaluation, including a complete history and physical
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examination, baseline serum hCG levels, and hepatic, thyroid, and renal function
tests. Basic metastatic work-up includes a chest X-ray, computed tomographic (CT)
scan ofthe chest (ifindicated), ultrasonography ofthe abdomen and pelvis, and head
CT scan.
Duplexultrasound has recentlybeen shown tobe capable ofidentifying focal areas
of altered echogenicity within the uterus. When used in conjuction with Doppler
scanning to detect focal areas of altered blood flow, it can be a valuable tool to
identify otherwise occult metastases invarious organs [26].
Cerebral metastases, which are associated with increased mortality and morbidity,
have in the past proven difficult to diagnose. Two new techniques, however, have
altered the prognosis ofthis complication dramaticallybecause ofearlierdiagnosis-
head CT scanning and the plasma:CSF hCG ratio. The Charing Cross Group have
reported that a plasma:CSF hCG ratio of less than 60 strongly suggests central
nervous system involvement [27]. It must be emphasized, however, that rapid
changes in plasma hCG levels may not be promptly reflected in the cerebrospinal
fluid (CSF), making a single plasma:CSF hCG ratio misleading.
Treatment
The treatment of GTN should be individualized. Once the pre-treatment evalua-
tion is completed and the extent of disease determined, the patient should be
assigned a stage and a prognostic score. In general, low-risk patients with both
metastatic and non-metastatic disease usually respond to single-agent chemother-
apy, while patients with high-risk disease should be treated primarily with combina-
tion chemotherapy.
Ninety percent of patients with stage I (non-metastatic) disease are curable with
single-agent chemotherapy. Those patients who prove resistant to single-agent
chemotherapy ultimately respond tocombination chemotherapy. Forthis reason, the
distinction between low-risk and high-risk prognostic scores in patients with stage I
disease is not as important as it is in the other groups.
There does, however, exist a subset of stage I patients with histologically proven
choriocarcinoma and agreater than average tumorburden, as reflected in hCG titers
over50,000 mIU/ml, who have generally proven resistant to single-agent chemother-
apy and do best when treated with combination therapy initially. Pre-treatment
dilation and curettage has proven extremely helpful in identifying this small group of
patients, and for this reason this procedure should be a part of the initial work-up
[28].
Primary surgical treatment in patients with stage I disease who no longer wish to
preserve fertility is an acceptable alternative to chemotherapy alone. When primary
hysterectomy is performed, adjunctive single-agent chemotherapy should be utilized
in case viable tumor is disseminated at surgery and also to treat occult metastases.
Data from the Southeastern Trophoblastic Disease Center reveals that occult
pulmonary metastases are present on CT scans of the lung in about 40 percent of
patients with presumed non-metastatic disease [29]. Chemotherapy may be safely
administered at the time ofhysterectomywithout increasing operative morbidity.
The type ofchemotherapy selected for patients with stage II and stage III disease
should be based on the prognostic score. Low-risk patients in these categories are
managed initiallywith single-agent chemotherapy despite the presence ofmetastatic
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disease; however, high-riskpatients should alwaysbe treatedprimarilywithcombina-
tion chemotherapy. The cure rate should approach 100 percent.
Special attention mayneed tobe focused on the roleofsurgeryin the management
of stage II and stage III disease. Vaginal metastases may bleed profusely because
they are highly vascular and friable. Bleeding may be controlled by packing the
vagina and performing local excision. The administration of one or two courses of
chemotherapy may result in marked tumor regression and reduce vascularity.
Recently, the technique ofangiographic embolization ofthe hypogastric arteries has
proven tobe a successful and less invasive technique.
Thoracotomy has a limited role in the management of stage III disease. Thorac-
tomy should be performed ifthe diagnosis is seriously in doubt, since some primary
lung tumors can secrete hCG. Furthermore, if a patient has had a persistent viable
solitary pulmonary nodule by chest CT despite intensive chemotherapy, pulmonary
resection may be advantageous [30]. An extensive metastatic work-up should be
obtained, however, to exclude other sites of persistent disease. It is important to
emphasize that fibrotic nodules may persist indefinitely on chest roentgenogram
after complete gonadotropin remission is achieved. These should not be surgically
excised.
Hysterectomy may be required despite the desire to preserve fertility in patients
with metastases in ordertocontrol uterine hemorrhage orsepsis. Furthermore, it has
been reported that, in patients with bulky uterine tumor, hysterectomy may reduce
the tumorburden and therefore limit the need for chemotherapy.
All patients with stage IV disease should be treated with intensive combination
chemotherapy and the selective use of radiation therapy and surgery. Before 1975,
the survival rate of patients with stage IV disease was approximately 30 percent.
Since 1975, when primary combination chemotherapy was introduced, the complete
remission rate has risen to over 90 percent. This dramatic improvement in survival
resulted from a combination of factors, including the use of staging and prognostic
scoring systems, earlier diagnosis because of improved imaging techniques, and the
use of newer agents incorporated into well-proven protocols used intensively with
radiation therapy and surgery.
The management ofhepatic disease is particularly problematic and challenging. If
a patient is resistant to systemic chemotherapy, hepatic arterial infusion of chemo-
therapy has been shown to achieve complete remission in selected cases. Hepatic
resection may also be necessary to control bleeding or to excise resistant disease.
Ifcerebral metastases are detected, whole-brain irradiation is promptly instituted
at the NETDC. The concurrent administration of chemotherapy and brain irradia-
tion may reduce the risk ofspontaneous cerebral bleeding. Brain irradiation maybe
both hemostatic and tumoricidal. Craniotomy may be required to provide acute
decompression or to control bleeding. Infrequently, a solitary cerebral metastasis
that is resistant to chemotherapy may be amenable to resection. Fortunately,
patients with cerebral metastases who attain remission usually have no residual
neurologic defects.
SINGLE-AGENT CHEMOTHERAPY
Single-agent chemotherapy with either Methotrexateg(Mtx) or actinomycin D
(ACT D) has achieved comparable and excellent cure rates in both non-metastatic
and metastatic disease. Mtxand folinic acid (Mtx-FA) rescue has been the preferred
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single-agent protocol at the NETDC since 1974. Between 1974 and 1990, a total of
260 patients were treated with primary Mtx and FA rescue. Complete remission was
obtained in 86 percent, and 60 percent required only one course to achieve
remission. Mtx-FA rescue induced remission in 90 percent of patients with stage I
disease and 60 percent of patients with low-risk stage II and stage III tumor.
Resistance to Mtx was more common in patients with choriocarcinoma, when
metastases were present, and when the pre-treatment hCG level was greater than
50,000 mIU/ml. The toxicity following Mtx-FA rescue was quite low, with thrombo-
cytopenia, granulocytopenia, and hepatotoxicity occurring only in 2 percent, 6
percent, and 14 percent, respectively. No patients required transfusions or devel-
oped sepsis due to myelosuppression, and no patient experienced marked nausea or
alopecia.
CHEMOTHERAPY ADMINISTRATION
When patients with low-risk disease are treated with single-agent chemotherapy,
the hCG level is measured weekly after each course of chemotherapy. The hCG
regression curve serves as the primary basis for determining the need for further
treatment. After the first treatment, further chemotherapy is withheld as long as the
hCG level is falling progressively. Additional single-agent chemotherapy is not
administered at any predetermined or fixed interval time. Subsequent courses of
chemotherapy are administered under the following conditions: when the hCG level
plateaus for more than three consecutive weeks, re-elevates, or when the hCG level
does not decline by one logwithin 18 days after completing the first treatment.
If a second course of Mtx-FA is necessary, the dosage of Mtx is unchanged if the
patient's response to the first treatment is adequate. An adequate response is
defined as a decline in the hCG level by one log following a course ofchemotherapy.
When the response to the first treatment is inadequate, the patient is considered to
be resistant to Mtx and actinomycin D is then promptlysubstituted.
A relatively new drug, etoposide (VP16) has been demonstrated to be a highly
effective anti-tumor agent in GTN [31-32]. A triple-therapy regimen which includes
etoposide, Mtx-FA, and ACT D (EMA) has become the primary combination
regimen at the NETDC.
Patients who require combination chemotherapy must be treated intensively to
achieve remission. It is advisable to administer combination chemotherapy as
frequently as toxicitypermits (usually at two-week intervals) until the patient obtains
threeweekly normal hCGvalues. After the patient achieves normal hCGvalues, two
additional courses ofchemotherapy are administered to reduce the risk ofrelapse.
PLACENTAL SITE TROPHOBLASTIC TUMORS
In 1976, Kurman et al. described 12patientswith avariant oftrophoblastic disease
marked by a distinct and exaggerated placental site reaction [32]. The term "tropho-
blastic pseudotumor of the uterus" was coined to reflect the apparently benign
nature ofthe lesion. In 1981, Twiggs et al. reported the death ofayoungwomanwith
metastatic trophoblastic pseudotumor [33]. In 1981, Scully and Young published a
reappraisal ofthese rare tumors and suggested the term "placental site trophoblastic
tumor" (PSTT) to emphasize the potentially malignant nature ofthe lesion [34].
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Diagnosing this rare form of trophoblastic disease and predicting its biologic
behavior remain difficult despite knowledge of the histology of these lesions and
continued reporting ofseries ofpatients.
Diagnosis
PSTT may complicate or follow normal pregnancy, abortion, or hydatidiform
mole. Tumors are thought to arise from the intermediate trophoblastic cell. This
trophoblast functions in implantation and the establishment of the uteroplacental
circulation. Although the intermediate trophoblast can elaborate all placental
proteins, the major protein secreted is human placental lactogen (hPL). Histologi-
cally, PSTT is characterized by mononuclear and occasionally multinuclear giant
cells that infiltrate the uterus and its blood vessels. Chorionic villi are present very
rarely.
PSTT can be distinguished from gestational choriocarcinoma by its monomorphic
cell population and lack of necrosis and hemorrhage. Immunohistochemical studies
demonstrate variable reactivity, with a minority of cells staining for hCG, and the
majority staining for hPL.
ClinicalBehavior
PSTT may follow any type of gestation. The symptoms can appear from weeks to
years after termination ofthe pregnancy. Most patients presentwithin the first three
months with irregular vaginal bleeding. Rare presenting symptoms have been
reported and include virilization, amenorrhea, and nephrotic syndrome [35,36,37].
The variable and often low hCG expression in PSTT may be accounted for by the
paucity of syncytiotrophoblast. At the time of the clinical presentation, therefore,
hCG values are often low and certainly below the levels usually encountered with
other forms ofGTN.
Patients found to have PSTT on dilation and curettage should undergo a complete
work-up, including metastatic screening. The majority of patients, however, will be
found to have non-metastatic disease.
The clinical behavior ofPSTT remains enigmatic. Manypatients canbe curedwith
curettage alone, while others have died despite intensive multimodal therapy.
Metastases from PSTT occur mainly in the lungs, although metastases to lymph
nodes, brain, liver, kidney, vagina, stomach, and spleen have been reported [37]. A
major clinical dilemma in patients with PSTT is predicting which tumors have the
greatest risk of developing metastases. Levels of hCG and hPL have been poor
predictors of clinically aggressive behavior. Some authors have recommended the
use of mitotic counts to predict tumors with an increased likelihood of metastases;
however, mitotic counts vary substantially from endometrial curettings to hysterec-
tomy specimens to metastatic lesions. Basing further therapy on mitotic counts from
endometrial curettings therefore may be misleading. Using a proposed cutoff of
more than four mitoses per 10 high-power fields to dictate when a hysterectomy
should be performed may not be useful. Therefore, patients with PSTT and low
mitotic counts may also develop disseminated tumors.
Treatment
Metastatic PSTT is an ominous sign since this tumor is relatively insensitive to
aggressive cytotoxic chemotherapy. Although few if any long-term survivors with
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metastatic PSTT have been reported, radiotherapy mayhave a role in providing local
control of the tumor and palliating the symptoms. Early hysterectomy is recom-
mended for treatment of non-metastatic disease and may also be useful in patients
with metastases, since the uterus is usually infiltratedwith tumor.
Serial hCG levels should be measured over long periods oftime because metasta-
ses have been reported to occur as late as ten years after the presentation. Because
little hCG is secreted, a large tumor burden may be present before the hCG levels
are detectable.
SUBSEQUENT REPRODUCTIVE PERFORMANCE
Patients with GTN usually can achieve complete sustained remission without
undergoing hysterectomy. After completing hormonal follow-up, most patients
thereafter are confronted with a decision about attempting future pregnancy.
Therefore, it is helpful to have data on later pregnancies to counsel these patients
rationally.
The NETDC has collected data on later pregnancies for 30 years. When patients
complete gonadotropin follow-up, they are requested to inform the Center about any
later conceptions. Furthermore, every two to three years the Center mails question-
naires to all patients in the registry concerning their general health problems and
later pregnancies. Patients are informed of the data from the questionnaires in our
yearly newsletter.
PregnanciesAfter Complete MolarPregnancy
Patients who were treated for complete mole at the NETDC had 1,162 later
gestations between June 1, 1965, and December 31, 1989. These subsequent concep-
tions resulted in 803 term live births (69.1 percent), six stillbirths (0.05 percent), 84
premature deliveries (7.2 percent), and nine ectopic pregnancies (0.8 percent).
Fifteen (1.3 percent) of the later gestations were either complete or partial moles.
Major and minorcongenital malformations were detected atbirth in 35 (3.9percent)
of the infants; no particular anomalywas noted. First- and second-trimester sponta-
neous abortions developed in 190 (16.4 percent) and 18 (1.5 percent) of the
pregnancies, respectively. The risk of stillbirth, prematurity, malformations, and
spontaneous abortion was comparable to that in the general population.
The frequency of intrapartum complications was determined by assessing the
primary cesarean section rate in later gestations. Primary cesarean section was
performed in 49 (17 percent) of 288 later-term and premature deliveries between
January 1979 and December 1989. Patientswith complete mole, therefore, are not at
greater than normal risk ofneeding cesarean delivery in later gestations.
Patients with complete hydatidiform mole were reassured that they can expect a
normal reproductive outcome in the future.
PregnanciesAfterPartialMolarPregnancy
Between June 1, 1965, and December 31, 1989, patients with partial molar
pregnancy at the NETDC had 107 later gestations, resulting in 79 term live births
(73.9 percent), one stillbirth (0.9 percent), one premature delivery (0.9 percent), and
one ectopic pregnancy (0.9 percent). First- and second-trimester spontaneous abor-
tions occurred in 16 (14.9 percent) and one (0.9 percent) pregnancies, respectively.
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Only two (2.5 percent) of 81 term or premature infants had detectable major or
minor congenital malformations. Primarycesarean sectionwasperformed in 13 (16.2
percent) of80 term or premature births between January 1979 and December 1989.
Similarly, patients with partial molar pregnancy appear to have normal reproduc-
tive function subsequent to their evaluation.
RepeatMolarPregnancy
Patients with molar disease (either partial or complete) are at increased risk of
developing molar pregnancy in later conceptions [38,39]. The incidence of repeat
hydatidiform mole hasbeen reported as0.6-2.0 percent in laterpregnancies in North
America and Asia [40-42]. Furthermore, Sand et al. reported that, after two
episodes ofgestational trophoblastic neoplasia, the risk of repeat disease rises to 28
percent [39].
We have observed every possible combination of repeat molar disease in our 15
patients with repeat moles [43]. Seven patients had consecutive complete moles, and
two had repeat partial moles. Six patients developed both a complete and partial
hydatidiform mole; five patients had an initial complete mole followed by a partial
mole, and one patient had an initial partial mole followedby a complete mole. These
patients may have a predilection for abnormal fertilization that causes either
complete orpartial mole.
Patients with repeat molar disease may ultimately have a normal pregnancy. Four
of our patients with repeat mole later completed normal, full-term pregnancies.
Lurain et al. also reported that five of eight patients with consecutive moles
subsequently achieved normal, termgestations [43].
Patients with repeat moles are at increased risk of developing persistent GTN in
later episodes of molar disease. Only one (7 percent) of our 15 patients with repeat
mole developed persistent tumor after herfirst molargestation; however, six patients
(40percent) developed persistent tumor after their second or third molarpregnancy.
Parazzini et al. also observed a threefold increased risk of post-molar tumor in
patients with repeat molar disease [44].
PregnanciesAfterPersistent GTN
Reports from the National Cancer Institute, Charing Cross Hospital (London),
Beijing Union Medical College Hospital, and Hong Kong all indicate that patients
with GTN who are managed successfully with chemotherapy can expect normal
reproduction in the future [46-50]. Van Thiel et al. studied later gestations in 50
women with GTN who were treated at the NCI. Those women had 88 subsequent
pregnancies that resulted in 71 full-term deliveries (81 percent), five spontaneous
abortions (17 percent), and two stillbirths (2 percent). Congenital malformations
were detected in only three full-term infants (4 percent). Ross also reviewed the
experience at the NCI and observed no increase in congenital anomalies in later
pregnancies in patients with GTN.
Walden and Bagshawe reported observing 64 later gestations in patients with
GTN who were treated at Charing Cross Hospital. Those subsequent pregnancies
concluded in 45 full-term deliveries (70.3 percent), ten spontaneous abortions (15.6
percent), five premature births (7.8 percent), and four stillbirths (6.3 percent). Only
three full-term infants (4.7 percent) had congenital anomalies. The cumulative dose
ofchemotherapy had no effect upon subsequent fertility or fetal wastage.
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The potential influence of chemotherapy upon later fertility and congenital
anomalieswas investigated further at Charing Cross Hospital by Rustin et al. Among
217 women who wished to conceive after chemotherapy for GTN, 200 (92 percent)
conceived, and 187 (86 percent) succeeded in having at least one live birth. There
was no significant difference in the ability to conceive or the outcome of later
pregnancyinwomenover30 ascompared tothose 30orunder. Womenwhoreceived
three ormore drugs incombinationwere less likelyto conceive or to have a live birth
than were women who received methotrexate alone or methotrexate with one other
agent. A total of 368 pregnancies resulted in 273 live births (74.2 percent), 53
spontaneous abortions (14.4 percent), eight stillbirths (2.2 percent), and two ectopic
pregnancies (0.6 percent). Five (1.8 percent) of the live-born infants had major
congenital anomalies.
Song and colleagues reviewed 355 subsequentpregnancies in patients treatedwith
chemotherapy for GTN in Beijing. The subsequent gestations concluded in 279 term
births (78.6 percent), 20 premature deliveries (5.6 percent), 26 spontaneous abor-
tions (7.3 percent), three stillbirths (0.8 percent), and two ectopic pregnancies (0.6
percent).
Patients at the NETDC who received chemotherapy for GTN had 385 later
conceptions between June 1, 1965, and December 31, 1989. Those pregnancies
resulted in 275 term live births (71.4 percent), six stillbirths, 14 premature deliveries,
and four ectopic pregnancies. Major or minor malformations were detected at birth
in six (2 percent) of 295 term or premature infants. First- and second-trimester
abortions occurred in 15 and 2 percent of the pregnancies, respectively. Primary
cesarean section was performed for 14.8 percent of 189 term or premature deliveries
between January 1979 and December 1989. The data from the NETDC on later
pregnancies in patients with GTN are consistent with the experience reported from
Washington, London, Beijing, and Hong Kong.
ManagementofSubsequent Pregnancies
Patients with GTN should be counseled that they generally have the same
expectation for normal future pregnancies as does the average woman in the United
States. After a patient has had a molar gestation, however, any future conception is
at increased riskofdeveloping GTN. It is therefore advisable forpatients to undergo
ultrasonography in the first trimester to confirm normal development. The placenta
or products of conception from subsequent pregnancies should undergo careful
pathologic examination. Furthermore, a serum hCG level should be obtained six
weeks after the completion of any future gestation to exclude subsequent choriocar-
cinoma.
CONCLUSION
This review covers the most important aspects ofmolar pregnancyand GTN in the
1990s that physicians need to know in advising patients with this disease. Dramatic
progress has occurred in the understanding and treatment of this group of diseases
because of the tireless commitment of many investigators worldwide. It is expected
that during the next decade additional progress will be made in the treatment ofthe
small remaining group of patients with resistant disease, as newer diagnostic
techniques and more effective agents are developed.
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